Compare ZDGE & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDGE | NSPR |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 33.7M |
| IPO Year | 2016 | 2009 |
| Metric | ZDGE | NSPR |
|---|---|---|
| Price | $3.03 | $0.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 109.0K | 85.7K |
| Earning Date | 06-11-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ 73.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,398,000.00 | $2,310,000.00 |
| Revenue This Year | $3.27 | $57.98 |
| Revenue Next Year | $5.78 | $95.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.21 | $0.63 |
| 52 Week High | $4.70 | $2.93 |
| Indicator | ZDGE | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.25 | 39.07 |
| Support Level | $2.89 | $0.69 |
| Resistance Level | $3.16 | $1.04 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 15.79 | 71.29 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.